BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next

For most of the last decade, the strategic case for running Asia-Pacific clinical trials could be summarised in a single word: China. A vast, treatment-n...

June 29, 2026 | Analysis

Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 for EGFR-Mutant Lung Cancer

Racura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung ...

June 29, 2026 | News

Everest Medicines' LEROCHOL® BLA Accepted in China for Third-Generation PCSK9 Inhibitor

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing an...

June 29, 2026 | News

The Frontier That Won’t Quite Arrive

Ask the region’s clinical-operations leaders whether decentralised and hybrid trials are the future, and the answer is almost unanimous. Surveys keep...

June 26, 2026 | Analysis

C-Ray Therapeutics Secures Radiopharmaceutical Production Licence, Strengthening CRDMO Capabilities in China

C-Ray Therapeutics (Chengdu) Co., Ltd. ("C-Ray Therapeutics") completed on-site inspections conducted by a panel of experts from the Sichuan Provincial Cen...

June 25, 2026 | News

Mabwell Secures China Clinical Trial Approval for First-in-Class LILRB4/CD3 Bispecific T-Cell Engager in Blood Cancers

Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical P...

June 25, 2026 | News

UniXell Secures US FDA Clearance for Off-the-Shelf Parkinson’s Cell Therapy, Advancing Dual-China-US Clinical Development

UniXell Biotechnology Co., Ltd. ("UniXell") has secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for UX-DA...

June 25, 2026 | News

AnHorn Medicines Secures FDA IND Clearance for First-in-Class CIPN Prevention Candidate

AnHorn Medicines announced that its lead neuroprotective candidate AH-008, being developed for the prevention of chemotherapy-induced peripheral neuro...

June 24, 2026 | News

China Approves World's First CAR-T Therapy for Solid Tumours

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as informed by...

June 24, 2026 | News

Europe Greenlights BRAFTOVI, Cetuximab and FOLFOX Regimen for Previously Untreated BRAF-Mutant mCRC

uropean approval is based on results from the Phase 3 BREAKWATER trial, which demonstrated that encorafenib in combination with cetuximab and mFOLFOX6 de...

June 24, 2026 | News

DoH Abu Dhabi and Sanofi Deepen Partnership to Build Next-Generation Vaccine Innovation Hub

The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Sanofi, a worldwide biopharma and vaccines...

June 24, 2026 | News

Avance Clinical Expands APAC And China Operations To Accelerate Global Biotech Trials

Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO) for biotechs, announced a significant expansion of its Asia Pacif...

June 22, 2026 | News

Qihan Biotech’s Universal CAR-T Therapy QT-019B Secures FDA’s ‘Triple Crown’ of Expedited Designations

Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology to c...

June 18, 2026 | News

Gesynta Pharma Reaches 50% Patient Enrollment in Phase II Endometriosis Trial of Vipoglanstat

Gesynta Pharma AB, a Swedish clinical stage pharmaceutical company focusing on chronic inflammatory diseases, today announced that 50% of the target of 190...

June 18, 2026 | News

Stay Connected